78 related articles for article (PubMed ID: 21625079)
1. Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis.
Liwei L; Chunyu L; Jie L; Ruifa H
Urol Int; 2011; 87(2):159-64. PubMed ID: 21625079
[TBL] [Abstract][Full Text] [Related]
2. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1395-402. PubMed ID: 14693728
[TBL] [Abstract][Full Text] [Related]
4. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis.
Shaik AP; Jamil K; Das P
Urol J; 2009; 6(2):78-86. PubMed ID: 19472123
[TBL] [Abstract][Full Text] [Related]
5. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.
Wang J; Stockton DW; Ittmann M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6169-78. PubMed ID: 15448004
[TBL] [Abstract][Full Text] [Related]
6. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):618-24. PubMed ID: 12869400
[TBL] [Abstract][Full Text] [Related]
7. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
[TBL] [Abstract][Full Text] [Related]
8. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
Ho CK; Anwar S; Nanda J; Habib FK
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):94-6. PubMed ID: 19918264
[TBL] [Abstract][Full Text] [Related]
9. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis.
Wang C; Sun Y; Han R
Urology; 2008 Oct; 72(4):869-72. PubMed ID: 18336890
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
11. Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls.
Qi X; Ma X; Yang X; Fan L; Zhang Y; Zhang F; Chen L; Zhou Y; Jiang J
Breast Cancer Res Treat; 2010 Sep; 123(2):499-506. PubMed ID: 20135343
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
[TBL] [Abstract][Full Text] [Related]
14. Association between CAG repeat polymorphisms and the risk of prostate cancer: a meta-analysis by race, study design and the number of (CAG)n repeat polymorphisms.
Sun JH; Lee SA
Int J Mol Med; 2013 Nov; 32(5):1195-203. PubMed ID: 23982466
[TBL] [Abstract][Full Text] [Related]
15. Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects.
Lu PH; Yang J; Li C; Wei MX; Shen W; Shi LP; Jiang ZY; Zhou N; Tao GQ
Breast Cancer Res Treat; 2011 Apr; 126(3):663-70. PubMed ID: 20809358
[TBL] [Abstract][Full Text] [Related]
16. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
Ewart-Toland A; Chan JM; Yuan J; Balmain A; Ma J
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):759-64. PubMed ID: 15159307
[TBL] [Abstract][Full Text] [Related]
17. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.
Sun J; Wiklund F; Hsu FC; Bälter K; Zheng SL; Johansson JE; Chang B; Liu W; Li T; Turner AR; Li L; Li G; Adami HO; Isaacs WB; Xu J; Grönberg H
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):480-5. PubMed ID: 16537705
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
19. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis.
Tao W; Wang C; Han R; Jiang H
Breast Cancer Res Treat; 2009 Mar; 114(2):371-6. PubMed ID: 18438707
[TBL] [Abstract][Full Text] [Related]
20. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population.
Medeiros R; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Lopes C
J Hum Genet; 2002; 47(8):413-8. PubMed ID: 12181642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
